PubMed Health⌕ Search

Biomedical subjects

M Dada

Publications and source records attributed to M Dada.

4 recordsLinked to original sources
PubMed1997

CD31 (JC70) expression in plasma cells: an immunohistochemical analysis of reactive and neoplastic plasma cells.

AIMS: To investigate the immunohistochemical expression of CD31 (JC70) in normal and neoplastic plasma cells. METHODS: Plasma cells in bone marrow biopsies and extramedullary locations were examined. All extramedullary biopsies were formalin fixed and paraffin embedded. The bone marrow biopsies were fixed in formal acetic acid and embedded in paraffin wax. Twenty multiple myelomas (12 bone marrow and eight extramedullary deposits), 10 extramedullary plasmacytomas, and 30 biopsies with reactive plasma cells (10 bone marrow, 20 extramedullary biopsies) were stained with anti-CD31 (JC70) using the streptavidin-biotin detection system with diaminobenzidine as a chromogen. Antigen retrieval in bone marrow biopsies was achieved by pressure cooking. In all other biopsies, antigen retrieval was achieved by microwave pretreatment. RESULTS: All 20 extramedullary cases with reactive plasma cells showed intense membrane staining. Focal staining was detected in reactive plasma cells in bone marrow biopsies. Five of 10 plasmacytomas showed membrane staining. None of the cases of multiple myeloma, either medullary or extramedullary, showed any immunoreactivity for CD31. CONCLUSIONS: CD31, a member of the immunoglobulin supergene family of cell adhesion molecules, is strongly expressed in extramedullary reactive plasma cells, focally in bone marrow reactive plasma cells, and occasionally in extramedullary plasmacytomas.

Cohort Studies↗
PubMed1992

Prospective payment for psychiatric services.

The Medicare prospective payment system (PPS) was designed to create financial incentives for providers to contain costs, but it also places them at financial risk. The system includes provisions to mitigate the risk, but, because they may have limited effectiveness in the case of psychiatric services, specialty psychiatric hospitals and eligible psychiatric units of general hospitals are exempt from the system. A variety of payment options have been proposed to integrate these facilities into the PPS. Empirical studies on the financial risk entailed by these options have focused on their impact on risk in the long run. Our study uses a broader framework to evaluate their impact on short-run as well as long-run risk. We use Medicare discharge data for 1985 to simulate alternative PPS payment options under the assumption that treatment patterns remain fixed. Our results suggest that under current PPS payment rules, risk would be high for psychiatric specialty hospitals. However, alternative options exist, which could substantially reduce their exposure to risk, while maintaining incentives to contain costs.

Cost Control↗